Kawaguchi T, Fukushima S, Hayashi Y, Kaneko M, Nakano M
Department of Pharmaceutical Sciences, Josai University, Saitama, Japan.
Cancer Res. 1988 Aug 1;48(15):4179-83.
Selective accumulation/retention of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine (FdUrd-C8) and sustained release of its active metabolites, 5-fluoro-2'-deoxyuridine (FdUrd) and 5-fluoro-2'-deoxyuridylate (FdUMP), in the rabbit hepatoma (VX-2) were achieved following intrahepatic arterial administration of FdUrd-C8 solution in Lipiodol. Though no significant difference in the FdUrd-C8 levels among the tumor and nontumorous liver was observed immediately after administration, slower elimination of FdUrd-C8 from the tumor (t 1/2 = 15.8 h) than that from nontumorous sites (t 1/2 = 3.8-4.2 h) resulted in selective retention of FdUrd-C8 (17- to 157-fold) in the tumor. Selectively higher levels of FdUrd and FdUMP in the tumor were also achieved (5- to 35-fold) and kept for 72 h after administration. The selective accumulation was also demonstrated in radioactivity distribution after administration of [6-3H]-FdUrd-C8. The ratio of radioactivity in the tumor divided by that in the blood (T/B ratio) was in a range of 870 to 5400 during a 15- to 1440-min period after administration. A trace of radioactivity was found in the stomach, duodenum, kidneys, and bone marrow. Roles of activation and deactivation enzymes on the selective distribution of FdUrd-C8 were also investigated. Esterase activity, which is responsible for the regeneration of FdUrd from FdUrd-C8, was relatively low in the tumor before administration and gradually increased after administration. Phosphorylase activity, which is related to phosphorolytic cleavage of FdUrd, in the tumor was about 3/5 as much as that in the nontumorous liver. These enzyme activities seem to play limited roles in the selective accumulation/retention and regeneration of the drug.
在经肝动脉给予碘油中的3',5'-二辛酰基-5-氟-2'-脱氧尿苷(FdUrd-C8)溶液后,兔肝癌(VX-2)实现了FdUrd-C8的选择性蓄积/滞留及其活性代谢产物5-氟-2'-脱氧尿苷(FdUrd)和5-氟-2'-脱氧尿苷酸(FdUMP)的持续释放。给药后即刻,肿瘤和非肿瘤肝脏中的FdUrd-C8水平无显著差异,但肿瘤中FdUrd-C8的消除速度(t1/2 = 15.8小时)慢于非肿瘤部位(t1/2 = 3.8 - 4.2小时),导致肿瘤中FdUrd-C8选择性滞留(17至157倍)。给药后肿瘤中FdUrd和FdUMP水平也选择性升高(5至35倍)并维持72小时。给予[6-3H]-FdUrd-C8后,放射性分布也显示出选择性蓄积。给药后15至1440分钟内,肿瘤中的放射性与血液中的放射性之比(T/B比)在870至5400范围内。在胃、十二指肠、肾脏和骨髓中发现微量放射性。还研究了活化和失活酶在FdUrd-C8选择性分布中的作用。负责从FdUrd-C8再生FdUrd的酯酶活性在给药前肿瘤中相对较低,给药后逐渐升高。肿瘤中与FdUrd磷酸解裂解相关的磷酸化酶活性约为非肿瘤肝脏中的3/5。这些酶活性在药物的选择性蓄积/滞留和再生中似乎起有限作用。